

별첨 2

배제문헌

문헌배제사유

1. 동물연구 또는 전임상시험
2. 원자가 아닌 연구(종설, letter, comment 등)
3. 회색문헌
4. 한국어, 영어로 출판되지 않은 연구
5. 적절한 중재시술을 수행하지 않은 연구
6. 사전에 정의된 대상자를 대상으로 수행되지 않은 연구
7. 적절한 의료결과를 하나 이상 보고하지 않은 연구
8. 증례보고
9. 중복출판된 연구
10. 원문확보 불가
11. 증례연구

연번	서지정보	배제사유
1	Abdoerrachman H. Perceptual and acoustical assessments on spasmodic dysphonia: Pre and post - Botulinum toxin injection. Medical Journal of Indonesia. 1997;6(3):158-63.	7
2	Achem SR, Gerson LB. Distal esophageal spasm: An update. Current Gastroenterology Reports. 2013;15(9) (no pagination)(325).	2
3	Adams SG, Durkin LC, Irish JC, Wong DL, Hunt EJ. Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia. Laryngoscope. 1996;106(3 Pt 1):296-300.	7
4	Adams SG, Hunt EJ, Charles DA, Lang AE. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. Journal of Otolaryngology. 1993;22(3):171-5.	7
5	Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, et al. Botulinum toxin type A for treating voice tremor. Archives of Neurology. 2004;61(9):1416-20.	6
6	Ali SO, Thomassen M, Schulz GM, Hosey LA, Varga M, Ludlow CL, et al. Alterations in CNS activity induced by botulinum toxin treatment in spasmodic dysphonia: an H215O PET study. Journal of Speech Language & Hearing Research. 2006;49(5):1127-46.	7
7	Anari S, Carding PN, Hawthorne MR, Deakin J, Drinnan MJ. Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia. Laryngoscope. 2007;117(10):1888-92.	6
8	Baylor CR, Yorkston KM, Eadie TL, Maronian NC. The psychosocial consequences of BOTOX injections for spasmodic dysphonia: a qualitative study of patients' experiences. Journal of Voice. 2007;21(2):231-47.	5
9	Bender BK, Cannito MP, Murry T, Woodson GE. Speech intelligibility in severe	5

연번	서지정보	배제사유
	adductor spasmodic dysphonia. Journal of Speech Language & Hearing Research. 2004;47(1):21-32.	
10	Benninger MS, Gardner G, Grywalski C. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Archives of Otolaryngology -- Head & Neck Surgery. 2001;127(9):1083-5.	5
11	Bhattacharyya N, Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Archives of Otolaryngology -- Head & Neck Surgery. 2001;127(4):389-92.	6
12	Bielamowicz S, Ludlow CL. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia. Annals of Otology, Rhinology & Laryngology. 2000;109(2):194-203.	7
13	Bielamowicz S, Stager SV, Badillo A, Godlewski A. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. Journal of Voice. 2002;16(1):117-23.	7
14	Birkent H, Maronian N, Waugh P, Merati AL, Perkel D, Hillel AD. Dosage changes in patients with long-term botulinum toxin use for laryngeal dystonia. Otolaryngology - Head and Neck Surgery. 2009;140(1):43-7.	7
15	Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 2015;125(8):1751-7.	9
16	Blitzer A, Brin MF. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin. Journal of Voice. 1992;6(4):365-9.	2
17	Blitzer A. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngology - Head & Neck Surgery. 2005;133(6):836-8.	5
18	Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. European Journal of Neurology. 2010;17 Suppl 1:28-30.	2
19	Braden MN, Johns MM, 3rd, Klein AM, Delgaudio JM, Gilman M, Hapner ER. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception. Journal of Voice. 2010;24(2):242-9.	7
20	Bradley JP, Barrow EM, Hapner ER, Klein AM, Johns MM, 3rd. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years. Journal of Voice. 2017;31(3):363-5.	7
21	Brin MF, Blitzer A, Stewart C. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. Advances in Neurology. 1998;78:237-52.	9
22	Brin MF, Blitzer A, Stewart CF, Diamond B, and Pogoda JM. Botulinum toxin type A for adductor spasmodic dysphonia (laryngeal dystonia): double blind placebo controlled assessment of dose and technique. Neurology. 2001;Vol.56(8 (Suppl 3)):A346p.	3
23	Brin MF, Stewart C, Blitzer A, Diamond B. Laryngeal botulinum toxin injections for disabling stuttering in adults. Neurology. 1994;44(12):2262-6.	6
24	Buchholz DW, Neumann S. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia. Dysphagia. 1997;12(1):59-60.	2
25	Cannito MP, Kahane JC, Chorna L. Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection. Clinical Interventions In Aging. 2008;3(1):131-51.	7
26	Cassery P, Timon C. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia. Journal of Laryngology & Otology. 2008;122(1):52-6.	7
27	Castellanos PF, Gates GA, Esselman G, Song F, Vannier MW, Kuo M. Anatomic considerations in botulinum toxin type A therapy for spasmodic dysphonia. Laryngoscope. 1994;104(6 Pt 1):656-62.	7
28	Cha W, Jang JY, Wang SG, Kang JH, Jo MG. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study. Journal of Voice. 2017;31(3):378.e19-.e24.	7
29	Chang CY, Chabot P, Thomas JP. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia. Otolaryngology - Head & Neck Surgery. 2007;136(6):894-9.	7

연번	서지정보	배제사유
30	Chitkara A, Meyer T, Keidar A, Blitzler A. Sieger's dystonia: First report of a variant of spasmodic dysphonia. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> . 2006;115(2):89-92.	5
31	Costello D. Spasmodic dysphonia. <i>Otorhinolaryngologist</i> . 2014;7(1):19-22.	2
32	Courey MS, Garrett CG, Billante CR, Stone RE, Portell MD, Smith TL, et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. <i>Annals of Otolaryngology, Rhinology & Laryngology</i> . 2000;109(9):819-22.	7
33	Damrose JF, Goldman SN, Groessl EJ, Orloff LA. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. <i>Journal of Voice</i> . 2004;18(3):415-22.	6
34	Davidson BJ, Ludlow CL. Long-term effects of botulinum toxin injections in spasmodic dysphonia. <i>Annals of Otolaryngology, Rhinology & Laryngology</i> . 1996;105(1):33-42.	7
35	Dejonckere PH, Neumann KJ, Moerman MB, Martens JP, Giordano A, Manfredi C. Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin. <i>European Archives of Oto-Rhino-Laryngology</i> . 2012;269(4):1195-203.	5
36	Dharia I, Bielamowicz S. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort. <i>Laryngoscope</i> . 2020;130(11):2659-62.	7
37	Elmiyeh B, Prasad VM, Upile T, Saunders N, Youl BD, Epstein R, et al. A single-centre retrospective review of unilateral and bilateral Dysport injections in adductor spasmodic dysphonia. <i>Logopedics, Phoniatrics, Vocology</i> . 2010;35(1):39-44.	11
38	Engelhoven AER, Zraick RI, Bursac Z, Tulunay-Ugur O, Hadden K. The Effects of Self-Esteem, Coping, and Voice-Related Quality of Life on Communicative Participation Before and After BOTOX R Treatment for Spasmodic Dysphonia. <i>Journal of Voice</i> . 2022;36(1):146.e5-.e16.	6
39	Epstein R, Stygall J, Newman S. The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia. <i>Disability & Rehabilitation</i> . 1997;19(1):20-5.	5
40	Faham M, Torabinezhad F, Murry T, Dabirmoghaddam P, Abolghasemi J, Kamali M, et al. Quality of Life and Voice Changes After a Single Injection in Patients With ADSD Over Time. <i>Journal of Voice</i> . 2019;33(5):721-7.	6
41	Finnegan EM, Luschei ES, Gordon JD, Barkmeier JM, Hoffman HT. Increased stability of airflow following botulinum toxin injection. <i>Laryngoscope</i> . 1999;109(8):1300-6.	8
42	Fisher KV, Giddens CL, Gray SD. Does botulinum toxin alter laryngeal secretions and mucociliary transport? <i>Journal of Voice</i> . 1998;12(3):389-98.	11
43	Fisher KV, Scherer RC, Guo CG, Owen AS. Longitudinal phonatory characteristics after botulinum toxin type A injection. <i>Journal of Speech & Hearing Research</i> . 1996;39(5):968-80.	8
44	Fisher KV, Scherer RC, Swank PR, Giddens C, Patten D. Electrolaryngographic tracking of phonatory response to Botox. <i>Journal of Voice</i> . 1999;13(2):203-18.	7
45	Fleming BM, Schwab EL, Nouer SS, Wan JY, LeDoux MS. Prevalence, predictors, and perceived effectiveness of complementary, alternative and integrative medicine in adult-onset primary dystonia. <i>Parkinsonism and Related Disorders</i> . 2012;18(8):936-40.	6
46	French G, Bosch JD, Randall DR. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort. <i>Journal of Otolaryngology: Head and Neck Surgery</i> . 2020;49(1):4.	7
47	Fulmer SL, Merati AL, Blumin JH. Efficacy of laryngeal botulinum toxin injection: comparison of two techniques. <i>Laryngoscope</i> . 2011;121(9):1924-8.	11
48	Gacek RR. Botulinum toxin for relief of spasmodic dysphonia. <i>Archives of Otolaryngology -- Head & Neck Surgery</i> . 1987;113(11):1240.	2
49	Galardi G, Guerriero R, Amadio S, Leocani L, Teggi R, Melloni G, et al. Sporadic failure of botulinum toxin treatment in usually responsive patients with adductor spasmodic dysphonia. <i>Neurological Sciences</i> . 2001;22(4):303-6.	11

연번	서지정보	배제사유
50	Gama AC, Menezes LN, Maia AA, Rezende Neto AL, Oliveira JB. Voice related quality of life after botulinum toxin injection for spasmodic dysphonia. <i>Revue de Laryngologie Otologie Rhinologie</i> . 2010;131(1):39-44.	7
51	Garcia Ruiz PJ, Cenjor Espanol C, Sanchez Bernardos V, Astarloa R, Sanabria J, Garcia de Yebenes J. Botulinum toxin treatment for spasmodic dysphonia: percutaneous versus transoral approach. <i>Clinical Neuropharmacology</i> . 1998;21(3):196-8.	11
52	Geneid A, Lindestad P, Granqvist S, Moller R, Sodersten M. Long-Term Follow-Up of Patients with Spasmodic Dysphonia and Improved Voice despite Discontinuation of Treatment. <i>Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP)</i> . 2016;68(3):144-51.	5
53	Gibbs SR, Blitzler A. Botulinum toxin for the treatment of spasmodic dysphonia. <i>Otolaryngologic Clinics of North America</i> . 2000;33(4):879-94.	2
54	Gochman GE, Dwyer CD, Young VN, Rosen CA. Exploring Patient's Preference of Patient-Reported Outcome Measures in Laryngeal Movement Disorders. <i>Laryngoscope</i> . 2022;31:31.	6
55	Green DC, Berke GS, Ward PH, Gerratt BR. Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. <i>Annals of Otology, Rhinology & Laryngology</i> . 1992;101(11):883-7.	5
56	Haneefa H, Majeed NA. Role of Voice Quality Assessment Tools in Patients after Botulinum Injection for Spasmodic Dysphonia. <i>International Journal of Pharmaceutical and Clinical Research</i> . 2022;14(8):361-7.	6
57	Heyes R, Adler CH, Zhang N, Lott DG, Bansberg SF. Significance of age and sex in botulinum neurotoxin dosing for adductor spasmodic dysphonia. <i>World Journal of Otorhinolaryngology Head and Neck Surgery</i> . 2023.	11
58	Hillel AD, Maronian NC, Waugh PF, Robinson L, Klotz DA. Treatment of the interarytenoid muscle with botulinum toxin for laryngeal dystonia. <i>Annals of Otology, Rhinology and Laryngology</i> . 2004;113(5 Pt 1):341-8.	7
59	Hirose K, Asano K, Sakaguchi M, Nagao A, Nakahira M, Doi N, et al. Post-treatment clinical course following botulinum toxin injection therapy for adductor spasmodic dysphonia: Analysis of data from a placebo-controlled, randomized, double-blinded clinical trial in Japan. <i>Laryngoscope Investigative Otolaryngology</i> . 2021;6(5):1088-95.	9
60	Hogikyan ND, Wodchis WP, Spak C, Kileny PR. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. <i>Journal of Voice</i> . 2001;15(4):576-86.	7
61	Holden PK, Vokes DE, Taylor MB, Till JA, Crumley RL. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia. <i>Annals of Otology, Rhinology & Laryngology</i> . 2007;116(12):891-6.	11
62	Holzer SE, Ludlow CL. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia. <i>Laryngoscope</i> . 1996;106(1 Pt 1):86-92.	7
63	Hu A, Hillel A, Meyer T. Factors Associated With Patient-perceived Hoarseness in Spasmodic Dysphonia Patients. <i>Journal of Voice</i> . 2016;30(6):769.e23-e26.	7
64	Hu A, Hillel A, Zhao W, Meyer T. Anxiety and depression in spasmodic dysphonia patients. <i>World Journal Of Otorhinolaryngology - Head And Neck Surgery</i> . 2018;4(2):110-6.	6
65	Hu A, Isetti D, Hillel AD, Waugh P, Comstock B, Meyer TK. Disease-specific self-efficacy in spasmodic dysphonia patients. <i>Otolaryngology - Head & Neck Surgery</i> . 2013;148(3):450-5.	6
66	Hyodo M, Asano K, Nagao A, Hirose K, Nakahira M, Yanagida S, et al. Botulinum Toxin Therapy: A Series of Clinical Studies on Patients with Spasmodic Dysphonia in Japan. <i>Toxins</i> . 2021;13(12):25.	2
67	Inagi K, Ford CN, Bless DM, Heisey D. Analysis of factors affecting botulinum toxin results in spasmodic dysphonia. <i>Journal of Voice</i> . 1996;10(3):306-13.	6
68	Isetti D, Meyer T. Workplace productivity and voice disorders: a cognitive interviewing study on presenteeism in individuals with spasmodic dysphonia. <i>Journal of Voice</i> . 2014;28(6):700-10.	7
69	Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind,	6

연번	서지정보	배제사유
	placebo-controlled study. Neurology. 1987;37(4):616-23.	
70	Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. Journal of Neurology, Neurosurgery & Psychiatry. 1990;53(8):633-9.	6
71	Justicz N, Hapner ER, Josephs JS, Boone BC, Jinnah HA, Johns MM, 3rd. Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor. Laryngoscope. 2016;126(1):113-7.	6
72	Kang MS, Lee SJ, Choi HS, Lim JY. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia. Clinical otolaryngology : official journal of ENT UK. 2020;01.	7
73	Kendall KA, Leonard RJ. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor. Journal of Voice. 2011;25(1):114-9.	7
74	Kirke DN, Kaye R, Blitzer A. Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients. Laryngoscope. 2020;130(7):1746-9.	11
75	Kobayashi T, Niimi S, Kumada M, Kosaki H, Hirose H. Botulinum toxin treatment for spasmodic dysphonia. Acta Oto-Laryngologica Supplement. 1993;504:155-7.	11
76	Koriwchak MJ, Nettekville JL, Snowden T, Courey M, Ossoff RH. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia. Laryngoscope. 1996;106(12 Pt 1):1476-81.	6
77	Langeveld TP, Drost HA, Baatenburg de Jong RJ. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia. Annals of Otolaryngology, Rhinology & Laryngology. 1998;107(4):280-4.	11
78	Langeveld TP, Luteijn F, van Rossum M, Drost HA, Baatenburg de Jong RJ. Adductor spasmodic dysphonia and botulinum toxin treatment: the effect on well-being. Annals of Otolaryngology, Rhinology & Laryngology. 2001;110(10):941-5.	7
79	Lee SJ, Kang MS, Choi HS, Lim JY. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia. Otolaryngology - Head & Neck Surgery. 2021;164(4):815-20.	7
80	Lerner MZ, Lerner BA, Patel AA, Blitzer A. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia. Laryngoscope. 2017;127(5):1131-4.	7
81	Liu CY, Yu JM, Wang NM, Chen RS, Chang HC, Li HY, et al. Emotional symptoms are secondary to the voice disorder in patients with spasmodic dysphonia. General Hospital Psychiatry. 1998;20(4):255-9.	7
82	Liu TC, Irish JC, Adams SG, Durkin LC, Hunt EJ. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia. Journal of Otolaryngology. 1996;25(2):66-74.	6
83	Ludlow CL, Bagley J, Sheng Guang Y, Koda J. A comparison of injection techniques using botulinum toxin injection for treatment of the spasmodic dysphonias. Journal of Voice. 1992;6(4):380-6.	11
84	Ludlow CL, Naunton RF, Fujita M, Sedory SE. Spasmodic dysphonia: botulinum toxin injection after recurrent nerve surgery. Otolaryngology - Head & Neck Surgery. 1990;102(2):122-31.	5
85	Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology. 1988;38(8):1220-5.	7
86	Lundy DS, Lu FL, Casiano RR, Xue JW. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia. Journal of Voice. 1998;12(4):460-6.	11
87	Maloney AP, Morrison MD. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia. Journal of Otolaryngology. 1994;23(3):160-4.	11
88	Maronian NC, Waugh PF, Robinson L, Hillel AD. Tremor laryngeal dystonia: Treatment of the lateral cricoarytenoid muscle. Annals of Otolaryngology, Rhinology and Laryngology.	6

연번	서지정보	배제사유
	2004;113(5 l):349-55.	
89	McHenry M, Whatman J, Pou A. The effect of botulinum toxin A on the vocal symptoms of spastic dysarthria: a case study. Journal of Voice. 2002;16(1):124-31.	8
90	Mehanna R, Jankovic J. Respiratory disorders associated with dystonia. Movement Disorders. 2012;27(14):1816-9.	8
91	Mendelsohn AH, Berke GS. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study. Annals of Otology, Rhinology & Laryngology. 2012;121(4):231-8.	5
92	Meyer TK, Hu A, Hillel AD. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin. Laryngoscope. 2013;123 Suppl 6:S1-14.	6
93	Meyer TK, Spiekerman C, Kaye R, Blitzer A, Kamizi RS, Jiang L, et al. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia. JAMA Otolaryngology-- Head & Neck Surgery. 2021;147(9):804-10.	6
94	Meyer TK. The treatment of laryngeal dystonia (spasmodic dysphonia) with botulinum toxin injections. Operative Techniques in Otolaryngology - Head and Neck Surgery. 2012;23(2):96-101.	2
95	Miller RH, Woodson GE, Jankovic J. Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Archives of Otolaryngology -- Head & Neck Surgery. 1987;113(6):603-5.	8
96	Mor N, Tang C, Blitzer A. Botulinum Toxin in Secondarily Nonresponsive Patients with Spasmodic Dysphonia. Otolaryngology - Head & Neck Surgery. 2016;155(3):458-61.	6
97	Morzaria S, Damrose EJ. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia. Journal of Voice. 2012;26(3):378-80.	5
98	Murry T, Cannito MP, Woodson GE. Spasmodic dysphonia. Emotional status and botulinum toxin treatment. Archives of Otolaryngology -- Head & Neck Surgery. 1994;120(3):310-6.	6
99	Namin AW, Christopher KM, Eisenbeis JF. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period. Journal of Voice. 2017;31(1):107-10.	7
100	Nelson RC, Silva Merea V, Tierney WS, Milstein C, Benninger MS, Bryson PC. Laryngeal Botulinum Toxin Injection for Vocal Tremor: Utility of Concurrent Strap Muscle Injection. Laryngoscope. 2019;129(6):1433-7.	6
101	Nerurkar NK, Banu TP. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population. Journal of Laryngology & Otology. 2014;128(7):649-53.	11
102	Nida A, Alston J, Schweinfurth J. Primidone Therapy for Essential Vocal Tremor. JAMA Otolaryngology-- Head & Neck Surgery. 2016;142(2):117-21.	6
103	O'Connell Ferster AP, Sataloff RT, Shewokis PA, Hu A. Socioeconomic Variables of Patients with Spasmodic Dysphonia: A Preliminary Study. Journal of Voice. 2018;32(4):479-83.	6
104	Odderson IR. Can botulinum toxin cause chronic muscle weakness? Muscle and Nerve. 2018;57(3):350-2.	2
105	O'Flynn L C, Simonyan K. Short- and Long-term Central Action of Botulinum Neurotoxin Treatment in Laryngeal Dystonia. Neurology. 2022;99(11):E1178-E90.	7
106	Orbelo DM, Duffy JR, Hughes Borst BJ, Ekblom D, Maragos NE. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor. Journal of Voice. 2014;28(1):123-7.	11
107	Paniello RC, Barlow J, Serna JS. Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results. Laryngoscope. 2008;118(3):564-8.	7
108	Paniello RC, Edgar JD, Perlmutter JS. Vocal exercise versus voice rest following	5

연번	서지정보	배제사유
	botulinum toxin injections: a randomized crossover trial. <i>Annals of Otolaryngology, Rhinology & Laryngology</i> . 2009;118(11):759-63.	
109	Patel PN, Kabagambe EK, Starkweather JC, Keller M, Gamsarian V, Lee J, et al. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor. <i>JAMA Otolaryngology-- Head & Neck Surgery</i> . 2018;144(4):293-9.	11
110	Poungvarin N, Devahastin V, Viriyavejakul A. Treatment of various movement disorders with botulinum A toxin injection: an experience of 900 patients. <i>Journal of the Medical Association of Thailand</i> . 1995;78(6):281-8.	10
111	Rhew K, Fiedler DA, Ludlow CL. Technique for injection of botulinum toxin through the flexible nasolaryngoscope. <i>Otolaryngology - Head & Neck Surgery</i> . 1994;111(6):787-94.	5
112	Rodriguez AA, Ford CN, Bless DM, Harmon RL. Electromyographic assessment of spasmodic dysphonia patients prior to botulinum toxin injection. <i>Electromyography & Clinical Neurophysiology</i> . 1994;34(7):403-7.	5
113	Rosow DE, Parikh P, Vivero RJ, Casiano RR, Lundy DS. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia. <i>Otolaryngology - Head & Neck Surgery</i> . 2013;148(6):1003-6.	11
114	Rosow DE, Pechman A, Saint-Victor S, Lo K, Lundy DS, Casiano RR. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients. <i>Journal of Voice</i> . 2015;29(3):352-5.	7
115	Rubin AD, Wodchis WP, Spak C, Kileny PR, Hogikyan ND. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II. <i>Archives of Otolaryngology -- Head & Neck Surgery</i> . 2004;130(4):415-20.	7
116	Rumbach AF, Blitzer A, Frucht SJ, Simonyan K. An open-label study of sodium oxybate in Spasmodic dysphonia. <i>Laryngoscope</i> . 2017;127(6):1402-7.	5
117	Rutt A, Kennelly KD, Martinez-Paredes JF. Patient Experience Contributing to Outcomes of Laryngeal Botulinum Toxin Injection. <i>Journal of Voice</i> . 2022;36(2):272-6.	7
118	Salvatore AP, Cannito M, Biswas A, Sinard RJ. Longitudinal study of temporal speech alterations in an individual with adductor spasmodic dysphonia treated with botulinum toxin. <i>Journal of Medical Speech-Language Pathology</i> . 2007;15(1):67-82.	8
119	Sapienza CM, Cannito MP, Murry T, Branski R, Woodson G. Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-botox injection and within early stages of post-botox injection. <i>Journal of Speech Language & Hearing Research</i> . 2002;45(5):830-43.	5
120	Schonweiler R, Wohlfarth K, Dengler R, Ptak M. Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction. <i>Laryngoscope</i> . 1998;108(1 Pt 1):55-63.	5
121	Schuering JHC, Heijnen BJ, Sjogren EV, Langeveld APM. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective. <i>Laryngoscope</i> . 2020;130(3):741-6.	5
122	Shi LL, Simpson CB, Hapner ER, Jinnah HA, Johns MM, 3rd. Pharyngeal Dystonia Mimicking Spasmodic Dysphonia. <i>Journal of Voice</i> . 2018;32(2):234-8.	8
123	Shoffel-Havakuk H, Marks KL, Morton M, Johns MM, 3rd, Hapner ER. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia. <i>Laryngoscope</i> . 2019;129(2):448-53.	5
124	Shoffel-Havakuk H, Rosow DE, Lava CX, Hapner ER, Johns MM, 3rd. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey. <i>Laryngoscope</i> . 2019;129(7):1650-6.	6
125	Silverman EP, Garvan C, Shrivastav R, Sapienza CM. Combined modality treatment of adductor spasmodic dysphonia. <i>Journal of Voice</i> . 2012;26(1):77-86.	5
126	Simpson CB, Lee CT, Hatcher JL, Michalek J. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes. <i>Laryngoscope</i> . 2016;126(1):118-21.	5
127	Smith ME, Ford CN. Resistance to botulinum toxin injections for spasmodic dysphonia. <i>Archives of Otolaryngology -- Head & Neck Surgery</i> . 2000;126(4):533-5.	8

연번	서지정보	배제사유
128	Smith ME. Spasmodic dysphonia and laryngeal botulinum toxin injection. <i>Western Journal of Medicine</i> . 1993;159(1):74.	2
129	Srirompotong S, Saeseow P, Taweesaengsuksakul R, Kharmwan S, Srirompotong S. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital. <i>Journal of the Medical Association of Thailand</i> . 2006;89(12):2077-80.	11
130	Stewart CF, Sinclair CF, Kling IF, Diamond BE, Blitzer A. Adductor focal laryngeal Dystonia: correlation between clinicians' ratings and subjects' perception of Dysphonia. <i>Journal of Clinical Movement Disorders</i> . 2017;4:20.	5
131	Stone A, Powell ME, Hamers K, Fletcher KC, Francis DO, Courey MS, et al. Optimizing Botox regimens in patients with adductor spasmodic dysphonia and essential tremor of voice: A 31-year experience. <i>Laryngoscope Investigative Otolaryngology</i> . 2022;7(5):1499-505.	7
132	Sulica L, Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section. <i>Annals of Otolaryngology, Rhinology & Laryngology</i> . 2003;112(6):499-505.	11
133	Sulica L, Blitzer A. Botulinum toxin treatment of spasmodic dysphonia. <i>Operative Techniques in Otolaryngology - Head and Neck Surgery</i> . 2004;15(2):76-80.	2
134	Suppa A, Asci F, Saggio G, Marsili L, Casali D, Zarezadeh Z, et al. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin. <i>Parkinsonism & Related Disorders</i> . 2020;73:23-30.	5
135	Tang CG, Novakovic D, Mor N, Blitzer A. Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience. <i>Laryngoscope</i> . 2016;126(3):678-81.	5
136	Tanner K, Roy N, Merrill RM, Sauder C, Houtz DR, Smith ME. Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response. <i>Annals of Otolaryngology, Rhinology & Laryngology</i> . 2011;120(7):465-73.	6
137	Tewary AK. Correlation between clinical response and injection quality in treatment of spasmodic dysphonia. <i>Journal of Laryngology & Otolaryngology</i> . 1996;110(6):551-3.	11
138	Thomas JP, Siupsinskiene N. Frozen versus fresh reconstituted botox for laryngeal dystonia. <i>Otolaryngology - Head & Neck Surgery</i> . 2006;135(2):204-8.	11
139	Thompson AR. Botulinum toxin in the treatment of adductor spasmodic dysphonia. <i>Journal of the Arkansas Medical Society</i> . 1994;90(8):383-5.	10
140	Tisch SH, Brake HM, Law M, Cole IE, Darveniza P. Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients—an Australian experience. <i>Journal of Clinical Neuroscience</i> . 2003;10(4):434-8.	11
141	Upile T, Elmiyeh B, Jerjes W, Prasad V, Kafas P, Abiola J, et al. Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study. <i>Head & Face Medicine</i> . 2009;5:20.	11
142	Valenzuela D, Singer J, Lee T, Hu A. The Impact of Socioeconomic Status on Voice Outcomes in Patients With Spasmodic Dysphonia Treated With Botulinum Toxin Injections. <i>Annals of Otolaryngology, Rhinology & Laryngology</i> . 2019;128(4):316-22.	5
143	Vasconcelos S, Birkent H, Sardesai MG, Merati AL, Hillel AD. Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia. <i>Laryngoscope</i> . 2009;119(10):2004-7.	11
144	Venkatesan NN, Johns MM, Hapner ER, DelGaudio JM. Abductor paralysis after botox injection for adductor spasmodic dysphonia. <i>Laryngoscope</i> . 2010;120(6):1177-80.	11
145	Wang NM, Lu CS. Botulinum toxin management of adductor spasmodic dysphonia with vocal tremors. <i>Journal of Medical Speech-Language Pathology</i> . 2004;12(1):1-8.	7
146	Whurr R, Lorch M, Fontana H, Brookes G, Lees A, Marsden CD. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 1993;56(5):526-30.	11
147	Wingate JM, Ruddy BH, Lundy DS, Lehman J, Casiano R, Collins SP, et al. Voice handicap index results for older patients with adductor spasmodic dysphonia. <i>Journal of</i>	5

연번	서지정보	배제사유
	Voice. 2005;19(1):124-31.	
148	Woisard V, Liu X, Bes MCA, Simonetta-Moreau M. Botulinum toxin injection in laryngeal dyspnea. European Archives of Oto-Rhino-Laryngology. 2017;274(2):909-17.	6
149	Wong DL, Adams SG, Irish JC, Durkin LC, Hunt EJ, Charlton MP. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia. Journal of Otolaryngology. 1995;24(4):209-16.	7
150	Wong DL, Irish JC, Adams SG, Durkin LC, Hunt EJ. Laryngeal image analysis following botulinum toxin injections in spasmodic dysphonia. Journal of Otolaryngology. 1995;24(1):64-8.	7
151	Woo P. Simultaneous Botox and Augmentation Injection Laryngoplasty in Patients With Adductor Spasmodic Dysphonia (ASD) and Tremor. Journal of Voice. 2022;30:30.	6
152	Yershov D, Partridge R. Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia. Prague Medical Report. 2020;121(2):114-7.	8
153	Yiu Y, Baylor CR, Bamer AM, Shelly S, Klein AM, Garrett CG, et al. Validation of the Communicative Participation Item Bank as an Outcome Measure for Spasmodic Dysphonia. Laryngoscope. 2021;131(4):859-64.	6
154	Yorkston K, Baylor CR, Eadie T, Kapsner-Smith M. Perceptions regarding communicative participation in individuals receiving botulinum toxin injections for laryngeal dystonia. International Journal of Language & Communication Disorders. 2021;56(6):1296-315.	6
155	Young DL, Halstead LA. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues. Journal of Voice. 2014;28(5):614-7.	7
156	Young N, Blitzer A. Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique. Laryngoscope. 2007;117(11):2082-4.	7
157	Young VN, Kidane J, Gochman GE, Bracken DJ, Ma Y, Rosen CA. Abnormal Laryngopharyngeal Sensation in Adductor Laryngeal Dystonia Compared to Healthy Controls. Laryngoscope. 2022.	5
158	Zhao K, Guillaud M, Hu A. Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia. Annals of Otolaryngology, Rhinology & Laryngology. 2020;129(10):996-1002.	11
159	Zwirner P, Murry T, Swenson M, Woodson GE. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope. 1992;102(4):400-6.	9
160	김한수. 기능성 음성장애에서 보툴리눔 독소의 임상적 적용. 대한후두음성언어의학회지. 2019;30(1):12-4.	2
161	남도현, 최성희, 최재남, 최홍식. 내전형 경련성발성장애의 호흡압력과 공기역학적 특징. 음성과학. 2005;12(4):203-13.	7
162	박신희, 소윤경, 정한신, 손영익. 연속성 발성장애 환자에서 냉동 보관한 보툴리눔 독소 주입술의 효과. 대한음성언어의학회지. 2007;18(1):51-5.	11
163	장민지, 이윤세, 왕수건, 이병주. 음성 및 후두 질환에서 A형 보툴리눔 독소의 적용. 임상이비인후과. 2012;23(1):46-53.	2
164	최성희, 심현섭, 최홍식. 경련성 발성장애 환자의 의사소통태도 연구. Communication Sciences and Disorders. 2004;9(3):157-76.	7
165	최홍식, 문형진, 김홍윤, 김시찬, 김광문. 내전형 연속성 발성장애 환자에서 보툴리눔독소 주입술의효과. 대한이비인후과학회지 두경부외과학. 1997a;40(4):475-80.	5
166	최홍식, 서진원, 문형진, 이주환, 김광문. 보툴리눔독소를 이용한 연속성 발성장애의 치료에 있어 연성비인두경법과 Teletaryngoscope법의 비교. 대한후두음성언어의학회지. 1997b;8(2):199-203.	5
167	최홍식. 보툴리눔독소 주입에 의한 음성장애 및 언어장애의 치료. 음성과학. 1998;3(-):5-17.	6